Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17593362 | 0.82 | CYP3A4 (0.47) | CYP3A4GABRA1GABRB2TRPA1 | |
| SCHEMBL28210896 | 0.82 | CYP3A4 (0.60) | CYP3A4GABRA1GABRB2TRPA1 | |
| SCHEMBL4350038 | 0.81 | ALDH1A1 (0.43) | CYP3A4GABRA1GABRB2 | |
| SCHEMBL15352850 | 0.80 | CYP3A4 (0.66) | CYP3A4GABRA1GABRB2TRPA1 | |
| SCHEMBL1595410 | 0.76 | CYP3A4 (0.54) | CYP3A4GABRA1GABRB2TRPA1 | |
| SCHEMBL29662014 | 0.76 | CYP3A4 (0.54) | CYP3A4GABRA1GABRB2TRPA1 | |
| SCHEMBL27985693 | 0.73 | CYP3A4 (0.61) | CYP3A4GABRA1GABRB2TRPA1 | |
| SCHEMBL28249769 | 0.73 | CYP3A4 (0.50) | CYP3A4GABRA1GABRB2TRPA1 | |
| SCHEMBL163526 | 0.73 | CYP3A4 (0.50) | CYP3A4GABRA1GABRB2TRPA1 | |
| SCHEMBL17170062 | 0.70 | CYP3A4 (0.47) | CYP3A4GABRA1GABRB2TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10112954-B2 | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase | HANMI PHARM. CO., LTD. (KR) | 2018-10-30 | — | — | US | disclosed |
| EP-2791111-B1 | [4-(PIPERIDIN-4-YL)-NAPHTHALEN-2-YL]-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS FOR THE TREATMENT OF RESPIRATORY DISORDERS | HOFFMANN LA ROCHE (CH) | 2017-01-18 | — | — | EP | disclosed |
| EP-2877480-A1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | Universiteit van Gent (BE) | 2015-06-03 | — | — | EP | disclosed |
| EP-2791111-A1 | PIPERIDINYL NAPHTHYLACETIC ACIDS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-22 | — | — | EP | disclosed |
| WO-2014001204-A1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | UNIVERSITEIT GENT (BE) | 2014-01-03 | — | — | WO | disclosed |
| WO-2013087544-A1 | PIPERIDINYL NAPHTHYLACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-20 | — | — | WO | disclosed |
| US-20130150407-A1 | PIPERIDINYL NAPHTHYLACETIC ACIDS | HOFFMANN-LA ROCHE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20120302567-A1 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-11-29 | — | — | US | disclosed |
| US-7960387-B2 | 2-(3-phenyl-2-piperazinyl-3,4-dihydroquinazolin-4-yl)acetic acids as antiviral agents, especially against cytomegaloviruses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-14 | — | — | US | disclosed |
| EP-2063897-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2000069821-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-11-23 | — | — | WO | disclosed |
| WO-1999020617-A1 | ANTIINFLAMMATORY THIADIAZOLYL UREAS WHICH ACT AS LFA-1 AND MAC-1 INHIBITORS | ACTIVE BIOTECH AB (SE) | 1999-04-29 | — | — | WO | disclosed |
| EP-0848023-A1 | Low surface energy polyisocyanates and their use in one- or two-component coating compositions | Bayer Corporation (US) | 1998-06-17 | — | — | EP | disclosed |
| US-5747629-A | Low surface energy polyisocyanates and their use in one-or two-component coating compositions | BAYER CORPORATION (US) | 1998-05-05 | — | — | US | disclosed |
| EP-0682656-A1 | USE OF PHENYL HETEROARYL UREAS AS 5HT 2C? RECEPTOR ANTAGONISTS AND UREA COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 1995-11-22 | — | — | EP | disclosed |
| EP-0472492-B1 | Tris-perfluoroalkyl terminated neopentyl alcohols and derivatives therefrom | CIBA GEIGY AG (CH) | 1994-10-05 | — | — | EP | disclosed |
| WO-1994018170-A1 | USE OF PHENYL HETEROARYL UREAS AS 5HT2C RECEPTOR ANTAGONISTS AND UREA COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 1994-08-18 | — | — | WO | disclosed |
| EP-0472492-A1 | Tris-perfluoroalkyl terminated neopentyl alcohols and derivatives therefrom | CIBA-GEIGY AG (CH) | 1992-02-26 | — | — | EP | disclosed |
| US-5068397-A | Alcohols as intermediates for polyurethanes, polyesters and polycarbonates | CIBA-GEIGY CORPORATION (US) | 1991-11-26 | — | — | US | disclosed |
| EP-0348350-A1 | Heteroatom containing perfluoroalkyl terminated neopentyl glycols and polymers therefrom | CIBA-GEIGY AG (CH) | 1989-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302567-A1 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | CDK2, SBK3, CDK2AP1 | CYP3A4 3643/4885GABRA1 2904/4885GABRB2 3192/4885 |
| US-10112954-B2 | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase | CDK2, SBK3, CDK2AP1 | CYP3A4 3643/4885GABRA1 2904/4885GABRB2 3192/4885 |
| US-20130150407-A1 | PIPERIDINYL NAPHTHYLACETIC ACIDS | HRH2, HRH1, HRH3 | CYP3A4 2277/4885GABRA1 352/4885GABRB2 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.